←Psychosis
Study register · detail Systematic Review · Psychosis · 2020

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Larsen et al. ·Journal of Clinical Medicine Research Impact 1.3
Mixed GRADE High 172 citations
Samplek = 25 Studien
n = 927 Pat.
DurationJanuary 2000 to October 2019
ControlPlacebo or active control
EndpointEfficacy and safety of CBD
Blindingunklar
DesignSystematic Review
Cannabinoidcbd
Key finding

CBD showed mixed efficacy depending on indication, with a positive signal for anxiety disorders and schizophrenia, but no effect on cognitive function in psychosis.

Summary

Systematic review of k=25 studies (n=927, of which 22 RCTs) on CBD dosing, efficacy and safety in adults; short-term therapeutic effects for psychotic disorders (symptomatic improvement in schizophrenia), social anxiety disorder and substance use disorders; no effect on cognitive function in psychosis; overall good tolerability.

P
PopulationAdults with somatic and psychiatric disorders (including anxiety disorder, psychosis, substance use disorder), n=927
I
InterventionCannabidiol (CBD), various formulations, doses and routes of administration
C
ControlPlacebo or active control (in 22 controlled studies)
O
OutcomeAnxiolytic effects with acute CBD administration; therapeutic effects in social anxiety disorder, psychotic disorder and substance use disorder; no effect on cognitive function in psychosis; generally well tolerated with mild side effects
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Mixed
Citations / year ★★★★★
Authors
Larsen C, Shahinas J
DOI 10.14740/jocmr4090↗
Design: Systematic Review
Share
Indication
Further studies on Psychosis
All studies →
S Belvederi Murri et al. · 2025 · Neuroscience & Biobehavioral Reviews
3 citations
The association between cannabis use and paranoia: Meta-analysis of experimental and observational studies
Clear benefit Meta-Analyse (Bayesian Model-Averaged)

Bayesian Meta-Analyse über k=13 Studien (n=13.559) zu Cannabis und paranoiden Symptomen; experimentelle Studien (k=5): Cannabinoid-Teilnehmer entwickelten schwerere paranoide Symptome als Placebo (SMD=0.47, 95% CI 0.13–0.48, PPI=94%); Querschnittsstudien (k=4): Cannabis-User höhere Odds für Paranoia (OR=1.75, 95% CI 1.43–2.07, PPI=99%); prospektive Studien (k=3) zeigen Assoziation mit späterem Paranoia-Onset.

10.1016/j.neubiorev.2025.106269 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

n=79 RCTs (n=6.462), umfassende SR zu medizinischem Cannabis; identifiziert psychotische Symptome als häufige Nebenwirkung (moderate Evidenz), keine therapeutische Evidenz für Psychose-Behandlung; relevante Sicherheitsdaten.

10.1001/jama.2015.6358 View study →
A Wilson et al. · 2026 · The lancet. Psychiatry
3 citations
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis.
Mixed Meta-Analyse

Systematische Review + Meta-Analyse zu Cannabinoiden bei psychischen Störungen und Substanzstörungen; k=54 RCTs (n=2.477, 69% männlich, medianes Alter 33,3 Jahre). 44% der Studien mit hohem Bias-Risiko, Evidenzqualität meist niedrig. CBD+THC-Kombination reduzierte Cannabis-Entzugssymptome (SMD=-0.29, 95% CI -0.57 bis -0.02) und wöchentlichen Cannabis-Konsum (-1.00g, 95% CI -1.69 bis [Daten unvollständig im Abstract]).

10.1016/s2215-0366(26)00015-5 View study →

The impediment to action advances action. — Marcus Aurelius